Novartis's secukinumab extends lead in IL-17 psoriatic arthritis race
This article was originally published in Scrip
Novartis is planning global regulatory filings for its interleukin-17A inhibitor secukinumab (AIN457) in 2015 after reporting that it met its endpoints in two pivotal Phase III trials in psoriatic arthritis. The latest developments position it to become the first IL-17 inhibitor to reach the market for the indication. However, the lack of data comparing it with current biological therapies may limit its commercial potential.